# A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MLS101 in Healthy Participants

> **NCT06326606** · PHASE1 · COMPLETED · sponsor: **MycoMedica Life Sciences PBC** · enrollment: 24 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Psilocybin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06326606
- **Lead sponsor:** MycoMedica Life Sciences PBC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-03-27
- **Primary completion:** 2024-07-08
- **Final completion:** 2024-07-08
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2024-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06326606

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06326606, "A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MLS101 in Healthy Participants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06326606. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*